TenX Keane Acquisition(TENK) - 2024 Q3 - Quarterly Results

CRANFORD, N.J., December 27, 2024 -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024. - Began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024, following completion of the merger of Citius Pharma's oncology subsidiary with TenX Keane ...